236 related articles for article (PubMed ID: 22231391)
1. Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuximab and nimotuzumab in A431 cells.
González JE; Barquinero JF; Lee M; García O; Casaco A
Cancer Biol Ther; 2012 Jan; 13(2):71-6. PubMed ID: 22231391
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
[TBL] [Abstract][Full Text] [Related]
4. Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
Eke I; Cordes N
Radiother Oncol; 2011 Jun; 99(3):279-86. PubMed ID: 21704406
[TBL] [Abstract][Full Text] [Related]
5. [Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].
Azria D; Larbouret C; Robert B; Culine S; Ychou M; Verrelle P; Dubois JB; Pèlegrin A
Bull Cancer; 2003 Nov; 90 Spec No():S202-12. PubMed ID: 14763141
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status.
Akashi Y; Okamoto I; Iwasa T; Yoshida T; Suzuki M; Hatashita E; Yamada Y; Satoh T; Fukuoka M; Ono K; Nakagawa K
Br J Cancer; 2008 Feb; 98(4):749-55. PubMed ID: 18253126
[TBL] [Abstract][Full Text] [Related]
7. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
Harari PM; Huang SM
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137
[TBL] [Abstract][Full Text] [Related]
8. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.
Saleh MN; Raisch KP; Stackhouse MA; Grizzle WE; Bonner JA; Mayo MS; Kim HG; Meredith RF; Wheeler RH; Buchsbaum DJ
Cancer Biother Radiopharm; 1999 Dec; 14(6):451-63. PubMed ID: 10850332
[TBL] [Abstract][Full Text] [Related]
9. EGFR-targeting monoclonal antibodies in head and neck cancer.
Astsaturov I; Cohen RB; Harari PM
Curr Cancer Drug Targets; 2006 Dec; 6(8):691-710. PubMed ID: 17168674
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab in squamous cell head and neck carcinomas.
Gebbia V; Giuliani F; Valori VM; Agueli R; Colucci G; Maiello E
Ann Oncol; 2007 Jun; 18 Suppl 6():vi5-7. PubMed ID: 17591832
[TBL] [Abstract][Full Text] [Related]
11. Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies.
Diaz Miqueli A; Rolff J; Lemm M; Fichtner I; Perez R; Montero E
Br J Cancer; 2009 Mar; 100(6):950-8. PubMed ID: 19293809
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
Herbst RS; Langer CJ
Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
[TBL] [Abstract][Full Text] [Related]
13. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
14. The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1α.
Lu H; Liang K; Lu Y; Fan Z
Cancer Lett; 2012 Sep; 322(1):78-85. PubMed ID: 22348829
[TBL] [Abstract][Full Text] [Related]
15. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
16. Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.
Bhuvaneswari R; Ng QF; Thong PS; Soo KC
Oncotarget; 2015 May; 6(15):13487-505. PubMed ID: 25918252
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab: its use in combination with radiation therapy and chemo-therapy in the multimodality treatment of head and neck cancer.
Wagner TD; Yang GY
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):76-83. PubMed ID: 18537749
[TBL] [Abstract][Full Text] [Related]
18. Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: a comparative study in glioblastoma cells.
Wichmann H; Güttler A; Bache M; Taubert H; Rot S; Kessler J; Eckert AW; Kappler M; Vordermark D
Strahlenther Onkol; 2015 Feb; 191(2):180-91. PubMed ID: 25159136
[TBL] [Abstract][Full Text] [Related]
19. Immune biomarkers of anti-EGFR monoclonal antibody therapy.
Trivedi S; Concha-Benavente F; Srivastava RM; Jie HB; Gibson SP; Schmitt NC; Ferris RL
Ann Oncol; 2015 Jan; 26(1):40-47. PubMed ID: 24997207
[TBL] [Abstract][Full Text] [Related]
20. Nimotuzumab enhances the radiosensitivity of cancer cells in vitro by inhibiting radiation-induced DNA damage repair.
Qu YY; Hu SL; Xu XY; Wang RZ; Yu HY; Xu JY; Chen L; Dong GL
PLoS One; 2013; 8(8):e70727. PubMed ID: 23976954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]